tNIV Vaccine

Vaccine

NNovavax

tNIV Vaccine is one of 24 biologic programs targeting Influenza. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Influenza

NCT06291857

Clinical

Trials by Indication[1]

Influenza2 trials

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Active, not recruiting·NNovavax·Phase 3·NCT06291857·9,320 enrolled

Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine

Withdrawn·NNovavax·Phase 2/3·NCT06485752

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for tNIV Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tNIV Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tNIV Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novavax company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Company: NNovavax

tNIV Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Influenza2 trials

References

Drug Info

Quick Facts

Related News